Evelo Biosciences, Inc. (NASDAQ:EVLO) management will conduct a conference call for 29th October 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.evelobio.com
Earnings Expectation
Evelo Biosciences, Inc. is set to announce third quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EVLO to report 3Q20 loss of $ 0.5 per share. For the full year, analysts anticipate loss of $ 2.23 per share bottom line.
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.
